Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension

Philip D Harvey, Cynthia O. Siu, Jay Hsu, Josephine Cucchiaro, Paul Maruff, Antony Loebel

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

This double-blind study evaluated change in cognitive performance and functional capacity in lurasidone and quetiapine XR-treated schizophrenia patients over a 6-week, placebo-controlled study, followed by a 6-month, double-blind extension. Cognitive performance and functional capacity were assessed with the CogState computerized cognitive battery and the UPSA-B. Analyses were conducted for all subjects, as well as the subsample whose test scores met prespecified validity criteria. No statistically significant differences were found for change in the composite neurocognitive score for lurasidone (80. mg/day and 160. mg/day) groups, quetiapine XR and placebo in the full sample at week 6. For the evaluable sample (N=267), lurasidone 160. mg was superior to both placebo and quetiapine on the neurocognitive composite, while lurasidone 80. mg, quetiapine XR, and placebo did not differ. UPSA-B scores were superior to placebo at 6 weeks for all treatments. In the double-blind extension study, analysis of the full sample showed significantly better cognitive performance in the lurasidone (40-160. mg) group compared to the quetiapine XR (200-800. mg) group at both 3 and 6 months. Cognitive and UPSA-B total scores were significantly correlated at baseline and for change over time. This is the first study to date where the investigational treatment was superior to placebo on both cognitive assessments and a functional coprimary measure at 6 weeks, as well as demonstrated superiority to an active comparator on cognitive assessments at 6 weeks and at 6 months of extension study treatment. These findings require replication, but are not due to practice effects, because of the placebo and active controls.

Original languageEnglish
Pages (from-to)1373-1382
Number of pages10
JournalEuropean Neuropsychopharmacology
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2013

Fingerprint

Schizophrenia
Placebos
Double-Blind Method
Placebo Effect
Investigational Therapies
Lurasidone Hydrochloride
Quetiapine Fumarate
Therapeutics

Keywords

  • Functional capacity
  • Lurasidone
  • Neurocognitive performance
  • Schizophrenia

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Biological Psychiatry
  • Neurology
  • Pharmacology

Cite this

Effect of lurasidone on neurocognitive performance in patients with schizophrenia : A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. / Harvey, Philip D; Siu, Cynthia O.; Hsu, Jay; Cucchiaro, Josephine; Maruff, Paul; Loebel, Antony.

In: European Neuropsychopharmacology, Vol. 23, No. 11, 01.11.2013, p. 1373-1382.

Research output: Contribution to journalArticle

@article{0759679b5833475d962b04c6344bdfb6,
title = "Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension",
abstract = "This double-blind study evaluated change in cognitive performance and functional capacity in lurasidone and quetiapine XR-treated schizophrenia patients over a 6-week, placebo-controlled study, followed by a 6-month, double-blind extension. Cognitive performance and functional capacity were assessed with the CogState computerized cognitive battery and the UPSA-B. Analyses were conducted for all subjects, as well as the subsample whose test scores met prespecified validity criteria. No statistically significant differences were found for change in the composite neurocognitive score for lurasidone (80. mg/day and 160. mg/day) groups, quetiapine XR and placebo in the full sample at week 6. For the evaluable sample (N=267), lurasidone 160. mg was superior to both placebo and quetiapine on the neurocognitive composite, while lurasidone 80. mg, quetiapine XR, and placebo did not differ. UPSA-B scores were superior to placebo at 6 weeks for all treatments. In the double-blind extension study, analysis of the full sample showed significantly better cognitive performance in the lurasidone (40-160. mg) group compared to the quetiapine XR (200-800. mg) group at both 3 and 6 months. Cognitive and UPSA-B total scores were significantly correlated at baseline and for change over time. This is the first study to date where the investigational treatment was superior to placebo on both cognitive assessments and a functional coprimary measure at 6 weeks, as well as demonstrated superiority to an active comparator on cognitive assessments at 6 weeks and at 6 months of extension study treatment. These findings require replication, but are not due to practice effects, because of the placebo and active controls.",
keywords = "Functional capacity, Lurasidone, Neurocognitive performance, Schizophrenia",
author = "Harvey, {Philip D} and Siu, {Cynthia O.} and Jay Hsu and Josephine Cucchiaro and Paul Maruff and Antony Loebel",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.euroneuro.2013.08.003",
language = "English",
volume = "23",
pages = "1373--1382",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Effect of lurasidone on neurocognitive performance in patients with schizophrenia

T2 - A short-term placebo- and active-controlled study followed by a 6-month double-blind extension

AU - Harvey, Philip D

AU - Siu, Cynthia O.

AU - Hsu, Jay

AU - Cucchiaro, Josephine

AU - Maruff, Paul

AU - Loebel, Antony

PY - 2013/11/1

Y1 - 2013/11/1

N2 - This double-blind study evaluated change in cognitive performance and functional capacity in lurasidone and quetiapine XR-treated schizophrenia patients over a 6-week, placebo-controlled study, followed by a 6-month, double-blind extension. Cognitive performance and functional capacity were assessed with the CogState computerized cognitive battery and the UPSA-B. Analyses were conducted for all subjects, as well as the subsample whose test scores met prespecified validity criteria. No statistically significant differences were found for change in the composite neurocognitive score for lurasidone (80. mg/day and 160. mg/day) groups, quetiapine XR and placebo in the full sample at week 6. For the evaluable sample (N=267), lurasidone 160. mg was superior to both placebo and quetiapine on the neurocognitive composite, while lurasidone 80. mg, quetiapine XR, and placebo did not differ. UPSA-B scores were superior to placebo at 6 weeks for all treatments. In the double-blind extension study, analysis of the full sample showed significantly better cognitive performance in the lurasidone (40-160. mg) group compared to the quetiapine XR (200-800. mg) group at both 3 and 6 months. Cognitive and UPSA-B total scores were significantly correlated at baseline and for change over time. This is the first study to date where the investigational treatment was superior to placebo on both cognitive assessments and a functional coprimary measure at 6 weeks, as well as demonstrated superiority to an active comparator on cognitive assessments at 6 weeks and at 6 months of extension study treatment. These findings require replication, but are not due to practice effects, because of the placebo and active controls.

AB - This double-blind study evaluated change in cognitive performance and functional capacity in lurasidone and quetiapine XR-treated schizophrenia patients over a 6-week, placebo-controlled study, followed by a 6-month, double-blind extension. Cognitive performance and functional capacity were assessed with the CogState computerized cognitive battery and the UPSA-B. Analyses were conducted for all subjects, as well as the subsample whose test scores met prespecified validity criteria. No statistically significant differences were found for change in the composite neurocognitive score for lurasidone (80. mg/day and 160. mg/day) groups, quetiapine XR and placebo in the full sample at week 6. For the evaluable sample (N=267), lurasidone 160. mg was superior to both placebo and quetiapine on the neurocognitive composite, while lurasidone 80. mg, quetiapine XR, and placebo did not differ. UPSA-B scores were superior to placebo at 6 weeks for all treatments. In the double-blind extension study, analysis of the full sample showed significantly better cognitive performance in the lurasidone (40-160. mg) group compared to the quetiapine XR (200-800. mg) group at both 3 and 6 months. Cognitive and UPSA-B total scores were significantly correlated at baseline and for change over time. This is the first study to date where the investigational treatment was superior to placebo on both cognitive assessments and a functional coprimary measure at 6 weeks, as well as demonstrated superiority to an active comparator on cognitive assessments at 6 weeks and at 6 months of extension study treatment. These findings require replication, but are not due to practice effects, because of the placebo and active controls.

KW - Functional capacity

KW - Lurasidone

KW - Neurocognitive performance

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84886799860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886799860&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2013.08.003

DO - 10.1016/j.euroneuro.2013.08.003

M3 - Article

C2 - 24035633

AN - SCOPUS:84886799860

VL - 23

SP - 1373

EP - 1382

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 11

ER -